{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T23:37:23Z","timestamp":1790206643091,"version":"4.1.0"},"reference-count":55,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,10,1]],"date-time":"2010-10-01T00:00:00Z","timestamp":1285891200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["amjmed.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The American Journal of Medicine"],"published-print":{"date-parts":[[2010,10]]},"DOI":"10.1016\/j.amjmed.2010.03.024","type":"journal-article","created":{"date-parts":[[2010,10,4]],"date-time":"2010-10-04T04:28:44Z","timestamp":1286166524000},"page":"892-898","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"title":["Treating Mixed Hyperlipidemia and the Atherogenic Lipid Phenotype for Prevention of Cardiovascular Events"],"prefix":"10.1016","volume":"123","author":[{"given":"Melvyn","family":"Rubenfire","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert D.","family":"Brook","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert S.","family":"Rosenson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.amjmed.2010.03.024_bib1","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1016\/j.jacc.2006.04.026","article-title":"AHA\/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update endorsed by the National Heart, Lung, and Blood Institute","volume":"47","author":"Smith","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2010.03.024_bib2","doi-asserted-by":"crossref","first-page":"1512","DOI":"10.1016\/j.jacc.2008.02.034","article-title":"Lipoprotein management in patients with cardiometabolic risk","volume":"51","author":"Brunzell","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2010.03.024_bib3","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1016\/j.jacc.2008.10.024","article-title":"Meta-analysis of the relationship between non-high-density lipoprotein cholesterol reduction and coronary heart disease risk","volume":"53","author":"Robinson","year":"2009","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2010.03.024_bib4","doi-asserted-by":"crossref","first-page":"3002","DOI":"10.1161\/CIRCULATIONAHA.107.713438","article-title":"Lipids, apolipoproteins, and their ratios in relation to cardiovascular events with statin treatment","volume":"117","author":"Kastelein","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2010.03.024_bib5","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2010.03.024_bib6","doi-asserted-by":"crossref","first-page":"2195","DOI":"10.1056\/NEJMoa0807646","article-title":"Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein","volume":"359","author":"Ridker","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2010.03.024_bib7","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.jacc.2006.04.070","article-title":"Meta-analysis of cardiovascular outcomes trials comparing intensive versus moderate statin therapy","volume":"48","author":"Cannon","year":"2006","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2010.03.024_bib8","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins","volume":"371","author":"Baigent","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2010.03.024_bib9","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/S0140-6736(08)60104-X","article-title":"Efficacy of cholesterol lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis","volume":"371","author":"Kearney","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2010.03.024_bib10","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1161\/CIRCULATIONAHA.106.667428","article-title":"Lipid management to reduce cardiovascular risk: a new strategy is required","volume":"117","author":"Superko","year":"2008","journal-title":"Circulation"},{"key":"10.1016\/j.amjmed.2010.03.024_bib11","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1016\/j.jacc.2007.10.038","article-title":"Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial","volume":"51","author":"Miller","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2010.03.024_bib12","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJMoa064278","article-title":"HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events","volume":"357","author":"Barter","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2010.03.024_bib13","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1001\/jama.297.5.499","article-title":"Statins, high-density lipoprotein cholesterol, and regression of coronary atherosclerosis","volume":"297","author":"Nicholls","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2010.03.024_bib14","doi-asserted-by":"crossref","first-page":"1583","DOI":"10.1056\/NEJMoa011090","article-title":"Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease","volume":"345","author":"Brown","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2010.03.024_bib15","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1016\/j.amjcard.2005.04.019","article-title":"Results of the National Cholesterol Education (NCEP) Program Evaluation Project Utilizing Novel E-Technology (NEPTUNE) II survey and implications for treatment under the recent NCEP Writing Group recommendations","volume":"96","author":"Davidson","year":"2005","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2010.03.024_bib16","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1056\/NEJMoa012512","article-title":"Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin","volume":"346","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2010.03.024_bib17","doi-asserted-by":"crossref","first-page":"969","DOI":"10.1001\/jama.297.9.969","article-title":"Comparison of Atkins, Zone, Ornish, and LEARN Diets for change in weight and related risk factors among overweight premenopausal women","volume":"297","author":"Gardner","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2010.03.024_bib18","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1016\/j.jacl.2007.02.005","article-title":"Effects of lifestyle intervention on high density lipoprotein cholesterol levels","volume":"1","author":"Roussell","year":"2007","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.amjmed.2010.03.024_bib19","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1016\/j.amjcard.2007.07.027","article-title":"Exercise training amount and intensity on metabolic syndrome (from Studies of a Targeted Risk Reduction Intervention through Defined Exercise","volume":"100","author":"Johnson","year":"2007","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2010.03.024_bib20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMoa050461","article-title":"Intensive lipid lowering with atorvastatin in patients with stable coronary disease","volume":"352","author":"LaRosa","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2010.03.024_bib21","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/S0140-6736(06)69292-1","article-title":"Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets Study","volume":"368","author":"Deedwania","year":"2006","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2010.03.024_bib22","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1097\/00019501-200403000-00008","article-title":"Rosuvastatin improves the atherogenic and atheroprotective lipid profiles in patients with hypertriglyceridemia","volume":"15","author":"Hunninghake","year":"2004","journal-title":"Coron Artery Dis"},{"key":"10.1016\/j.amjmed.2010.03.024_bib23","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1001\/jama.1975.03240160024021","article-title":"Clofibrate and niacin in coronary heart disease","volume":"231","year":"1975","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2010.03.024_bib24","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1016\/S0735-1097(86)80293-5","article-title":"Fifteen year mortality in Coronary Drug Project patients: long-term benefit with niacin","volume":"8","author":"Canner","year":"1986","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2010.03.024_bib25","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.amjcard.2005.08.070","article-title":"Benefits of niacin in patients with versus without the metabolic syndrome and healed myocardial infarction (from the Coronary Drug Project)","volume":"97","author":"Canner","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2010.03.024_bib26","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.atherosclerosis.2003.07.003","article-title":"Antiatherothrombotic effects of nicotinic acid","volume":"171","author":"Rosenson","year":"2003","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjmed.2010.03.024_bib27","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.amjcard.2004.04.024","article-title":"Safety and compliance with once-daily niacin extended-release\/lovastatin as Initial Therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) Study","volume":"94","author":"Rubenfire","year":"2004","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2010.03.024_bib28","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1016\/S0002-9149(00)00703-7","article-title":"Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia","volume":"85","author":"Goldberg","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2010.03.024_bib29","doi-asserted-by":"crossref","first-page":"1568","DOI":"10.1001\/archinte.162.14.1568","article-title":"Efficacy, safety, and tolerability of once daily niacin for the treatment of dyslipidemia associated with type 2 diabetes","volume":"162","author":"Grundy","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2010.03.024_bib30","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.jacl.2008.02.004","article-title":"Comparison of the efficacy and safety of combination tablet of niacin extended-release and simvastatin with simvastatin monotherapy: the SEACOAST II (high-dose) study","volume":"2","author":"Ballantyne","year":"2008","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.amjmed.2010.03.024_bib31","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1056\/NEJM199011083231901","article-title":"Regression of coronary artery disease as a result of intensive lipid-lowering therapy in men with high levels of apolipoprotein B","volume":"323","author":"Brown","year":"1990","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2010.03.024_bib32","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1056\/NEJMoa0907569","article-title":"Extended-release niacin or ezetimibe and carotid intima-media thickness","volume":"361","author":"Taylor","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2010.03.024_bib35","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1016\/S0140-6736(89)90828-3","article-title":"Effects of changes in fat, fish, and fibre intakes on death and myocardial reinfarction; diet and reinfarction trial (DART)","volume":"334","author":"Burr","year":"1989","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2010.03.024_bib36","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(99)07072-5","article-title":"Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial","volume":"354","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2010.03.024_bib37","first-page":"9645","article-title":"Effect of n-3 polyunsaturated fatty acids in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial","volume":"372","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2010.03.024_bib38","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.atherosclerosis.2008.06.003","article-title":"Effects of EPA on coronary artery disease in hypercholesterolemic patients with multiple risk factors: sub-analysis of primary prevention cases from the Japan EPA Lipid Intervention Study (JELIS)","volume":"200","author":"Saito","year":"2008","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.amjmed.2010.03.024_bib39","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.atherosclerosis.2006.02.012","article-title":"Effects of omega-3 fatty acids on serum markers of cardiovascular disease: a systematic review","volume":"189","author":"Balk","year":"2006","journal-title":"Atherosclerosis"},{"issue":"suppl","key":"10.1016\/j.amjmed.2010.03.024_bib40","doi-asserted-by":"crossref","first-page":"27i","DOI":"10.1016\/j.amjcard.2005.12.024","article-title":"Mechanisms for the hypotriglyceridemic effect of marine omega-3 fatty acids","volume":"98","author":"Davidson","year":"2006","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.amjmed.2010.03.024_bib41","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.jacl.2009.08.001","article-title":"Effects of prescription omega-3-acid ethyl esters on lipoprotein particle concentrations, apolipoproteins AI and CIII, and lipoprotein-associated phospholipase A2 mass in statin-treated subjects with hypertriglyceridemia","volume":"3","author":"Davidson","year":"2009","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.amjmed.2010.03.024_bib42","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1586\/14779072.6.10.1319","article-title":"Fenofibrate: treatment of hyperlipidemia and beyond","volume":"6","author":"Rosenson","year":"2008","journal-title":"Exp Rev Cardiovasc Ther"},{"key":"10.1016\/j.amjmed.2010.03.024_bib43","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.ahj.2007.07.011","article-title":"The role of fibrates in the prevention of cardiovascular disease-a pooled metaanalysis of long-term randomized placebo-controlled clinical trials","volume":"154","author":"Saha","year":"2007","journal-title":"Am Heart J"},{"key":"10.1016\/j.amjmed.2010.03.024_bib44","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1097\/MOL.0b013e3282f1ed84","article-title":"Fibrate therapy: safety considerations","volume":"18","author":"Usman","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.amjmed.2010.03.024_bib45","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1056\/NEJM198711123172001","article-title":"Helsinki Heart Study: a primary prevention trial with gemfibrozil in middle-aged men with dyslipidemia; safety of treatment, changes in risk factors, and incidence of coronary heart disease","volume":"317","author":"Frick","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2010.03.024_bib46","doi-asserted-by":"crossref","first-page":"1585","DOI":"10.1001\/jama.285.12.1585","article-title":"Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: a randomized controlled trial","volume":"285","author":"Robins","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2010.03.024_bib47","doi-asserted-by":"crossref","first-page":"2597","DOI":"10.1001\/archinte.162.22.2597","article-title":"Diabetes, plasma insulin, and cardiovascular disease: subgroup analysis from the Department of Veterans Affairs high-density lipoprotein intervention (VA-HIT)","volume":"162","author":"Rubins","year":"2002","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.amjmed.2010.03.024_bib48","doi-asserted-by":"crossref","first-page":"512","DOI":"10.5414\/CPP42512","article-title":"Assessment of a multiple-dose drug interaction between ezetimibe, a novel selective cholesterol absorption inhibitor and gemfibrozil","volume":"42","author":"Reyderman","year":"2004","journal-title":"Int J Clin Pharm Ther"},{"key":"10.1016\/j.amjmed.2010.03.024_bib49","doi-asserted-by":"crossref","first-page":"1849","DOI":"10.1016\/S0140-6736(05)67667-2","article-title":"Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised control trial","volume":"366","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.amjmed.2010.03.024_bib51","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1016\/j.metabol.2008.01.026","article-title":"Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia","volume":"57","author":"Tribble","year":"2008","journal-title":"Metab Clin Exp"},{"key":"10.1016\/j.amjmed.2010.03.024_bib52","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.jacc.2005.02.052","article-title":"Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia","volume":"45","author":"Koh","year":"2005","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.amjmed.2010.03.024_bib53","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1097\/MOL.0b013e32825a6773","article-title":"The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis","volume":"18","author":"Harper","year":"2007","journal-title":"Curr Opin Lipidol"},{"key":"10.1016\/j.amjmed.2010.03.024_bib54","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1016\/j.jclinepi.2006.11.006","article-title":"Statin and statin\u2014fibrate use was significantly associated with increased myositis risk in a managed care population","volume":"60","author":"McClure","year":"2007","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.amjmed.2010.03.024_bib55","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1016\/j.jacl.2008.10.001","article-title":"Long-term safety and efficacy of fenofibric acid in combination with statin therapy for the treatment of patients with mixed dyslipidemia","volume":"2","author":"Bays","year":"2008","journal-title":"J Clin Lipidol"},{"key":"10.1016\/j.amjmed.2010.03.024_bib56","doi-asserted-by":"crossref","first-page":"1563","DOI":"10.1056\/NEJMoa1001282","article-title":"Effects of combination lipid therapy in type 2 diabetes mellitus","volume":"362","author":"Ginsberg","year":"2010","journal-title":"N Engl J Med"},{"key":"10.1016\/j.amjmed.2010.03.024_bib57","doi-asserted-by":"crossref","first-page":"2622","DOI":"10.1001\/jama.292.21.2622","article-title":"Potential for conflict of interest in the evaluation of suspected adverse drug reactions: use of cerivastatin and risk of rhabdomyolysis","volume":"292","author":"Psaty","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.amjmed.2010.03.024_bib58","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.ahj.2007.12.011","article-title":"Medication nonadherence is associated with a broad range of adverse outcomes in patients with coronary artery disease","volume":"155","author":"Ho","year":"2008","journal-title":"Am Heart J"}],"container-title":["The American Journal of Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934310004651?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0002934310004651?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,11]],"date-time":"2025-09-11T08:54:09Z","timestamp":1757580849000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0002934310004651"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":55,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2010,10]]}},"alternative-id":["S0002934310004651"],"URL":"https:\/\/doi.org\/10.1016\/j.amjmed.2010.03.024","relation":{},"ISSN":["0002-9343"],"issn-type":[{"value":"0002-9343","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Treating Mixed Hyperlipidemia and the Atherogenic Lipid Phenotype for Prevention of Cardiovascular Events","name":"articletitle","label":"Article Title"},{"value":"The American Journal of Medicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.amjmed.2010.03.024","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2010 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}